Sangamo Therapeutics (SGMO) has entered into a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said Thursday.
The deal covers one neurological disease target with an option to add up to four additional targets.
The consideration for the deal includes a $20 million upfront license payment, potential payments of up to $1.3 billion in additional licensed target fees and milestone payments, as well as royalties on sales.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments